BioMed Research International / 2016 / Article / Tab 5

Research Article

A Retrospective Observational Study to Assess Prescription Pattern in Patients with Type B Aortic Dissection and Treatment Outcome

Table 5

Treatment strategy of antihypertensive drugs and event rate.

Treatment strategyNumber of patients%Event rate, (%)
Primary endpointsHosp.DeathSurgery

None1110.4%5 (45.5%)3 (27.3%)2 (18.2%)1 (9.1%)
Monotherapy109.4%2 (20.0%)1 (10.0%)1 (10.0%)0 (0%)
-blocker550.0%0 (0%)0 (0%)0 (0%)0 (0%)
 CCB110.0%0 (0%)0 (0%)0 (0%)0 (0%)
 Others440.0%1 (25.0%)1 (25.0%)1 (25.0%)0 (0%)
Dual therapy3129.3%8 (25.8%)6 (19.4%)3 (9.7%)4 (12.9%)
-blocker + CCB1858.1%3 (16.7%)3 (16.7%)0 (0%)2 (11.1%)
-blocker + Others516.1%2 (40.0%)2 (40.0%)2 (40.0%)2 (40.0%)
 CCB + RAS39.7%0 (0%)0 (0%)0 (0%)0 (0%)
 CCB + Others412.9%1 (25.0%)1 (25.0%)1 (25.0%)0 (0%)
 RAS + Others13.2%0 (0%)0 (0%)0 (0%)0 (0%)
Triple therapy4239.6%12 (28.6%)9 (21.4%)4 (9.5%)3 (7.1%)
-blocker + CCB + RAS1433.3%3 (21.4%)3 (21.4%)0 (0%)3 (21.4%)
-blocker + CCB + Others2047.6%5 (25.0%)5 (25.0%)1 (5.0%)0 (0%)
-blocker + RAS + Others49.5%1 (25.0%)1 (25.0%)2 (50.0%)0 (0%)
 CCB + RAS + Others49.5%0 (0%)0 (0%)1 (25.0%)0 (0%)
Quadruple therapy1211.3%3 (25.0%)1 (8.3%)2 (16.7%)1 (8.3%)

CCB: calcium channel blockers; RAS: drugs acting on the rennin-angiotensin system.
#Antihypertensive drugs divided into -blockers, drugs acting on the rennin-angiotensin system (including angiotensin converting enzyme inhibitors, angiotensin receptor blocker, and direct renin inhibitors), calcium channel blockers, and all other antihypertensive classes (including diuretics, -blockers, vasodilators, and central 2 agonists).
All-cause mortality and admission to hospital because of aortic dissection (primary endpoint). Hospitalization associated with aortic dissection. All-cause mortality. £ Referred to surgery repair.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.